News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Gemin X Biotechnologies Inc. To Present At The 25th Annual JPMorgan Healthcare Conference


12/21/2006 11:01:45 AM

MONTREAL--(BUSINESS WIRE)--Gemin X Biotechnologies Inc. announced today that Dan Giampuzzi, the Company’s president and chief executive officer, will present an overview of Gemin X’s clinical trial progress with lead product candidate, GX15-070, at the 25th Annual JPMorgan Healthcare Conference on Tuesday, January 9, at 4:30 PM Pacific time at the Westin St. Francis Hotel in San Francisco. GX15-070 is currently being evaluated in Phase 2 trials as a 24-hour infusion every two weeks in the treatment of Hodgkin's lymphoma and myelofibrosis with myeloid metaplasia.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES